The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth

Figure 1

Mechanism of action of VC in KRAS mutant cancer cells. Following the extracellular oxidation of VC to Dehydroascorbic Acid, it is transported into the cell by glucose transporter GLUT1. Inside the cell, DHA is converted back to reduced form at the expense of GSH and NADPH. Depletion of GSH and NADPH increases the ROS generation and DNA damage. Created with http://BioRender.com.